Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

What are the factors that cause oral mucositis to be severe after receiving radiation for head and neck cancer?

2.

Infection tied to one-fourth of deaths with lower-risk myelodysplastic syndromes

3.

In Sickle Cell Disease, Lovo-Cel is "Life-Changing, Transformative.".

4.

Sub-Q Ketamine is Safe and Very Effective for Severe Depression.

5.

Potential new therapy for childhood brain cancer could heal treatment-resistant tumors


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot